Toremifene: Difference between revisions
m (Protected "Toremifene": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
||
| Line 1: | Line 1: | ||
| Line 41: | Line 41: | ||
{{Sex hormones}} | {{Sex hormones}} | ||
[[Category:Selective estrogen receptor modulators]] | [[Category:Selective estrogen receptor modulators]] | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 16:59, 20 August 2012
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | more than 99.5% |
| Elimination half-life | 5 days |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C26H28ClNO |
| Molar mass | 405.959 g/mol |
|
WikiDoc Resources for Toremifene |
|
Articles |
|---|
|
Most recent articles on Toremifene |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Toremifene at Clinical Trials.gov Clinical Trials on Toremifene at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Toremifene
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Toremifene Discussion groups on Toremifene Patient Handouts on Toremifene Directions to Hospitals Treating Toremifene Risk calculators and risk factors for Toremifene
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Toremifene |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Toremifene citrate is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body. Licensed in the United States under the brand name Fareston, toremifene citrate is FDA approved for use in advanced (metastatic) breast cancer. It is also being evaluated for prevention of prostate cancer under the brand name Acapodene.[1]
GTx Inc. is currently conducting two different phase 3 clinical trials; First, a pivotal Phase clinical trial for the treatment of serious side effects of androgen deprivation therapy (especially vertebral/spine fractures and hot flashes, lipid profile, and gynecomastia) for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. Results of these trials are expected by first quarter of 2008[2]
References
- ↑ Price N, Sartor O, Hutson T, Mariani S. Role of 5a-reductase inhibitors and selective estrogen receptor modulators as potential chemopreventive agents for prostate cancer. Clin Prostate Cancer 2005;3:211-4. PMID 15882476
- ↑ "GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review" (Press release). GTx Inc. 2007-07-12. Retrieved 2006-07-14. Check date values in:
|date=(help)
- Pages with script errors
- CS1 errors: dates
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Selective estrogen receptor modulators
- Endocrinology